U.S. FDA Approves China-Produced Cancer Drug

An Akeso logo is displayed on the screen of an iPad. (Photo Illustration by Sheldon Cooper/SOPA ... More Images/LightRocket via Getty Images)
The U.S. Food and Drug Administration this week granted permission for the use of a new cancer drug from China despite high-profile strains in ties between the two countries.
Akeso said on Thursday it has received approval for treatments with penpulimab-kcqx, which is used in the fight against nasopharyngeal cancer, or NPC. In a separate announcement, the drug co-developer Sino Biopharmaceutical also noted FDA approval of the marketing of penpulimab.
NPC, a type of head and neck cancer, starts in the nasopharynx, the upper part of the throat behind the nose and near the base of skull, according to a description by the American Cancer Society. Cancer starts when cells begin to grow out of control, it noted.
China, the world's most populous nation, had a reported 3.2 million new cancer cases last year. A large number of cases has made the country one of the world's most important markets for cancer drugs.
Rare in most parts of the world, NPC is more common in certain parts of South Asia, the Middle East, and North Africa. In some parts of China there have been as many as 21 cases per 100,000 people, the American Cancer Society has said.
A logo of Sino Biopharmaceutical Limited hangs on a building at the central business district in ... More Beijing. (Photo by VCG/VCG via Getty Images)
Sino Biopharmaceutical, which listed on the Hong Kong Stock Exchange in 2000, is controlled by the billionaire family of Tse Ping. Akeso CEO Michelle Xia, who also goes by Xia Yu, ranked No. 20 on a list of China's top businesswomen published earlier this year by Forbes China, the licensed Chinese-language edition of Forbes.
Apple Supplier's Chairman Leads New List Of China's Top Businesswomen
CATL Battery Billionaire And Wife Donate $137 Million To Fudan

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

CNBC

3 hours ago

• CNBC

The lookahead: What next after U.S. strikes on Iran and Europe's 5% defense problem

After a week of global market jitters, the reaction to U.S. strikes on Iranian nuclear facilities will be front and center over the coming days. Meanwhile, a trio of heavyweight events could also shape the economic and geopolitical mood. From NATO tensions in The Hague to trade talks in Tianjin and industrial optimism in Berlin — investors will be watching closely. Addressing the nation on Saturday evening, U.S. President Donald Trump said strikes on three of Iran's nuclear sites were a "spectacular military success" that "completely obliterated" the country's major enrichment facilities. The strikes, which mark the first time the U.S. has conducted a direct military attack on Iran, mark a dramatic escalation in geopolitical tensions. Trump's claim about the result of the operation could not be independently confirmed. Iran Foreign Minister Abbas Araghchi slammed the U.S. strikes, describing them as "outrageous" and saying the country "reserves all options to defend its sovereignty, interest, and people." Global investors will be scrambling to assess the fallout. NATO meetings with Trump in attendance have a history of being dramatic. Back in 2017, the White House leader consistently questioned America's commitment to the alliance, and accused other members of owing "massive amounts of money" to the overall share of defense spending. Fast forward to 2025 and the next NATO Leaders Summit with Trump is set to take place in The Hague, the Netherlands on Wednesday. Some problems are familiar – while defense spending has increased dramatically across Europe, countries like Spain risk derailing talks by calling the 5% of GDP target "unreasonable." In addition, the war in Ukraine rages on. Meanwhile other problems are new – hostilities are rising between Israel and Iran, alongside other neighbors in the Middle East, are testing international relations to the limit. U.S. Ambassador to NATO Matthew Whittaker, told CNBC's "Squawk Box Europe" that the region should not expect a free ride from the U.S. on defense spending, as "the 5% target is not a negotiating tactic." On the other side of the world, the Chinese city of Tianjin plays host to the World Economic Forum's Meeting of New Champions running from Tuesday to Thursday, also known as the Summer Davos. Technology dominates the agenda at a tricky time for relations between China and the West, as trade negotiations with the U.S. are still on-going. Trump may have bought more time for TikTok, extending the deadline for China's ByteDance to divest the social media platform's U.S. business to September, but the latest round of trade talks in London led to a vague stand-off between the two superpowers, with no official readout. Speaking to CNBC right after those negotiations, U.S .Commerce Secretary Howard Lutnick was asked if current tariffs on China would not shift again, to which he replied, "you can definitely say that." But this may do little to ease the conversations between Chinese officials and corporates in Tianjin, and the international delegates in attendance, who will be looking for more certainty from both the White House and Beijing. Closer to home, it's the Day of Industry conference in Germany on Monday and Tuesday. This annual meeting in Berlin highlights German economic policy and global trade strategies. It could be a good time for the new government to be touting Europe's so-called Engine of Growth, with four economic institutes raising their 2025 and 2026 GDP growth forecasts for Europe's largest economy. During a recent trip to Washington DC, Chancellor Friedrich Merz dodged the ire that other world leaders have faced in the Oval Office, with Trump's focus mostly dominated by his public spat with Elon Musk. But it's not all clear roads ahead for Germany, as the country's auto industry body reports that domestic auto-makers have shouldered around 500 million euros ($576.1 million) in costs associated with Trump's import tariffs.

Business Upturn

13 hours ago

• Business Upturn

LPRO DEADLINE ALERT: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Open Lending Corporation Investors to Secure Counsel Before Important June 30 Deadline in Securities Class Action

NEW YORK, June 21, 2025 (GLOBE NEWSWIRE) — WHY: New York, N.Y., June 21, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Open Lending Corporation (NASDAQ: LPRO) between February 24, 2022 and March 31, 2025, both dates inclusive (the 'Class Period'), of the important June 30, 2025 lead plaintiff deadline. SO WHAT: If you purchased Open Lending securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Open Lending class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 30, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose materially adverse facts about Open Lending's business, operations, and prospects. Specifically, defendants: (1) misrepresented the capabilities of Open Lending's risk-based pricing models; (2) issued materially misleading statements regarding Open Lending's profit share revenue; (3) failed to disclose Open Lending's 2021 and 2022 vintage loans had become worth significantly less than their corresponding outstanding loan balances; (4) misrepresented the underperformance of Open Lending's 2023 and 2024 vintage loans; and (5) as a result of the foregoing, defendants' positive statements about Open Lending's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Open Lending class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]

Epoch Times

14 hours ago

• Epoch Times

How Women Can Prevent Hair Loss by Nourishing the Liver and Kidneys

Hair health reflects overall physical well-being. Women often experience hair loss due to various causes, including postpartum recovery, menopause, alopecia areata, or scalp issues such as itchiness and dandruff, exacerbated by summer heat. Traditional Chinese medicine (TCM) offers a holistic approach, emphasizing a blend of targeted dietary supplements, meticulous scalp care, and proper hair-washing techniques to reduce hair loss effectively. Dr. Chen Hsin-hung, a TCM practitioner at Hanyitang Chinese Medicine clinics in Taiwan, shared a case of hair loss. A woman in her 20s developed alopecia areata (patchy baldness) after receiving the COVID-19 vaccine, which left her deeply distressed when her hair almost entirely fell out. Through 6 to 8 months of TCM treatment, she regrew dark, vibrant hair. Exploring Hair Loss Causes With TCM From the perspective of TCM, the liver and kidneys are closely related to hair health as they play a vital role in the internal organ-centered energy system.